Navigation Links
Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
Date:12/11/2007

results in a small loss in the antiviral activity of PSI-6130 and is not highly polymorphic in the wild-type HCV population. These in vitro data indicate that there is a high genetic barrier to resistance to PSI-6130. Since PSI-6130 is metabolized to two active triphosphate forms, it is enticing to speculate that the two structurally different active metabolites would further increase the genetic barrier of PSI-6130.

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in the Americas and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an orally administered treatment for chronic HCV infection, is enrolling a 4-week Phase 1 clinical trial in combination with Pegasys(R) and Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

About Hepatitis B

Hepatitis B viruses can cause liver disease leading to significant morbidity and death. HBV can cause either acute or chronic (lifelong) infection. The World Health Organization (WHO) has reported that approximately 350 million people worldwide have chronic HBV infection. According to the Centers for Disease Control and Prevention (CDC), approximately 1.25 million people in the United States are chronically infected with HBV, and the Hepatitis B Foundation reports that 100,000 people will
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
2. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
3. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015  In a sweeping analysis assessing ... T1D Exchange researchers conclude that there remains ... diabetes across all age groups, but especially for adolescents ... picture of diabetes treatment, underscoring the need to address ... that can help type 1 patients achieve optimal metabolic ...
(Date:5/22/2015)... , May 22, 2015 AcelRx Pharmaceuticals, Inc. ... on the development and commercialization of innovative therapies for ... that interim chief executive officer Howie Rosen ... chief financial officer Tim Morris will be ... the two presentations are as follows: Jefferies ...
(Date:5/21/2015)... , May 21, 2015 ... ) has announced the addition of the ... Type (Ankle Replacement, Digit Replacement, Elbow Replacement, ... Forecast to 2019" report to their ... for knee replacement was valued at $4,470.9 ...
Breaking Medicine Technology:Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2North American Joint Reconstruction Market 2015-2019 - Zimmer Holdings, DePuy Synthes Companies, Stryker, Biomet & Smith & Nephew Dominates the $4.4 Billion Market 2
... , ROCKVILLE, Md., Dec. 9 Novavax, ... 25, 2009, it closed its previously announced public offering of ... Novavax received net proceeds from the sale of the ... approximately $21 million, which will be used for preclinical studies ...
... , GAITHERSBURG, Md, Dec. 9 Lentigen Corporation, ... of lentiviral gene delivery technologies, announced today that it ... business innovation research (SBIR) grant for a program on ... using Lentivirus". In this program, Lentigen will collaborate ...
Cached Medicine Technology:NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock 2Lentigen Awarded Phase I SBIR Grant for Hepatitis C Vaccine 2
(Date:5/23/2015)... With the implementation of the Affordable Care ... difficult to provide their employees with a viable healthcare ... for employees stand to face strict penalties. Never before ... of a business’s success or failure. In an effort ... Doctors has created a varying level of less expensive ...
(Date:5/23/2015)... May 23, 2015 Javon Bea ... the Sports Medicine and Rehabilitation Center, 557 N. Washington ... Mondays, June 1-July 20, 5:30-6:30 pm. , The 8-week ... and Laurie Finke, RN, BSN, who will offer training ... on nutrition, running mechanics and show selection and weekly ...
(Date:5/22/2015)... May 22, 2015 The American College ... events in June. They will hold a webinar on ... a two-day class on Classical Chinese Medicine. , Webinar ... Dr. Steve Given, the Dean of Clinical Education, will ... new First Professional Doctorate program. ACTCM is currently developing ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Omar Ahmad ... selected to participate in the 2015 Congress of Future ... described as a gathering of “America’s highest achieving high ... areas of healthcare, set new goals and learn better ... a live surgery, during which we can ask the ...
(Date:5/22/2015)... Pa (PRWEB) May 22, 2015 ... (AHN) today announced a new partnership to develop ... for the region. The initiative includes a new exhibit ... live demonstration theater, and a new traveling science ... the fall of 2015. , Designed to explore ...
Breaking Medicine News(10 mins):Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:ACTCM Announces Upcoming June Events 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4
... , Jan. 13 WellPoint, Inc. (NYSE: ... a "2010 Diversity Leader Award®" in the January/February issue of ... communication practices during the past year. , WellPoint continues ... inclusion practices and has received multiple honors in recent years ...
... ... products direct to patients which will reduce operating costs for providers and improve patient ... Plainview, ... announced today a strategic alliance designed to automate the shipping of CPAP products ...
... ... your health , ... the gym and cheaper than cosmetic surgery or even your nighttime moisturizer, turning up the heat ... and your health., , , , ,“An active sex life will make you healthier, buffer, younger ...
... ... advertising executive launches RedSquare360 to accommodate manufacturers, and web retailers, growing demands for 3D ... to help ecommerce clients increase conversion rates. , ... (PRWEB) January 13, 2010 -- Online retailers know the ...
... ... Microbix will maintain sales and marketing functions while Therapure will manage manufacturing, distribution ... ... Biosystems Inc. (MBX:TSX) a biotechnology company focused on virology and biological technologies, and ...
... ... firm striving to help families with wide range of legal needs. , ... New Brunswick, N.J. (Lexis Nexis) January 13, 2010 ... resources and skilled legal professionals that will help them navigate the state,s court system, ...
Cached Medicine News:Health News:WellPoint, Inc. Receives 2010 Diversity Leader Award(R) 2Health News:WellPoint, Inc. Receives 2010 Diversity Leader Award(R) 3Health News:Fastrack & cpapdropship.com Form Alliance to Reduce Provider Costs 2Health News:Fastrack & cpapdropship.com Form Alliance to Reduce Provider Costs 3Health News:Frequent and Fabulous Sex -- A Menopausal Woman's Surprising Fountain of Youth 2Health News:Frequent and Fabulous Sex -- A Menopausal Woman's Surprising Fountain of Youth 3Health News:360 Images Give Online Consumers A Product 'Demo' Before Purchasing. 2Health News:360 Images Give Online Consumers A Product 'Demo' Before Purchasing. 3Health News:Microbix and Therapure Biopharma Form Partnership to Expand Water-Based Supplies to the Pharma Industry 2Health News:Microbix and Therapure Biopharma Form Partnership to Expand Water-Based Supplies to the Pharma Industry 3Health News:Shamy & Shamy Launches New Web Site Providing Simple Access to Free Online Resources for New Jersey Court System 2
Serology provides a minimally-invasive, sensitive and easy-to-perform method for the determination of H. pylori infection. The Bio-Rad H. pylori qualitative test kits use EIA technology for the deter...
... effective and relatively bloodless procedure for immediate ... to learn and can be performed in ... setting with few if any patient complications. ... OR time and use a familiar technology ...
... IFA Test kit is a user-friendly ... in dropper bottles. A single monoclonal ... identify all serogroups of L. pneumophilia ... culture isolates, confirming a diagnosis of ...
... of the most innovative and elegantly simple ... provides an ideal solution for physicians seeking ... other option provides a better combination of ... System heats, circulates, and maintains precise control ...
Medicine Products: